Opus Genetics Launches Gene Therapy Trial for Blindness
Opus Genetics will launch a clinical trial of OPGx-MERTK, an adeno-associated virus gene therapy for MERTK-related retinitis pigmentosa, in...
Adaptive Clinical Trial Design Adaptive Trial Design Addiction Psychiatry AI in Clinical Trials alcohol use disorder Alzheimer's Disease Article Clinical Operations Clinical Research Clinical Trial Design Clinical Trial Operations Clinical Trial Ops Brief Clinical Trial Quality Clinical Trials CLINOPS WATCHDOG CNS Drug Development CNS Trials Conference Coverage Decentralized Clinical Trials Digital Health Technologies eClinical Tech News eClinical Technology EMA Executive Interviews FDA Enforcement FDA Guidance FDA Real-World Evidence FDA Regulation FDA Regulatory Strategy FDA Warning Letter GCP Compliance GLP-1 Receptor Agonists Ketamine Therapy Oncology Trials Opinion Parkinson's Disease Platform Trials Psilocybin MDMA Psychedelic Clinical Trials PSYCH PULSE Real-World Evidence site activation Site Operations study startup Treatment-Resistant Depression
Opus Genetics will launch a clinical trial of OPGx-MERTK, an adeno-associated virus gene therapy for MERTK-related retinitis pigmentosa, in...
Why competitive insight in the earliest stages of developing a therapy can determine ultimate success By Alex Angelopoulos, Life...
The University of Virginia has opened a first-in-human program for hCitH3-mAb, a monoclonal antibody intended to neutralize citrullinated histone...
The initiative will enroll up to 40 adults with PTSD for 12 weeks of adjunctive treatment with gammaCore Sapphire,...
Aligos has enrolled 144 patients into its Phase 2 B-SUPREME study of pevifoscorvir sodium (ALG-000184) in chronic hepatitis B,...
Exicure’s open-label, multicenter Phase 2 trial in multiple myeloma reported that 89.7% of patients met the study’s primary mobilization...
In a first-in-human pilot of 10 preoperatively potent men undergoing nerve‑sparing robotic radical prostatectomy, Comphya’s implantable cavernous nerve neurostimulator...
Daridorexant 50 mg met the primary endpoint of change from baseline in subjective total sleep time at Day 28...
In preclinical Lyme disease models, subtle alterations to the Borrelia burgdorferi peptidoglycan nearly eliminated arthritis despite ongoing infection at...
In preclinical models of diabetic macular edema, oral BGE-102 nearly eliminated retinal vascular leakage and preserved up to 90%...